⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SGMO News
Sangamo Therapeutics, Inc. Common Stock
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
globenewswire.com
SGMO
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
globenewswire.com
SGMO
Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2025 Financial Results
globenewswire.com
SGMO
Sangamo Therapeutics Announces Third Quarter 2025 Earnings Call
globenewswire.com
SGMO